The Gene Therapy Vector Facility at King’s College London announced the addition of the Univercells Technologies’ scale-X™ carbo bioreactor to its GMP manufacturing portfolio, further strengthening our capabilities for adeno associated virus (AAV) and lentiviral vector (LV) production.

The scale-X carbo bioreactor is a fixed-bed, single use bioreactor platform designed to support efficient and scalable adherent cell culture. Its compact footprint, high surface area, and modular design make it particularly well suited to viral vector manufacturing, enabling robust and reproducible production while supporting smooth scale up from development into GMP manufacture.

The introduction of the scale-X carbo platform will significantly enhance KCL’s ability to support technology transfer and scale up activities for both AAV and LV programmes. By offering a well-established and widely adopted bioreactor system, they can reduce development timelines, de risk process transfer, and provide greater flexibility for their current and future clients as programmes progress toward early clinical studies.

From a manufacturing perspective, the scale-X carbo bioreactor enables consistent process performance, efficient use of space, and streamlined operations within a GMP environment. These features support KCL’s commitment to delivering high quality viral vector while maintaining rigorous control of cost, quality, and timelines.

King’s College London GMP team has successfully completed installation and qualification of the scale-X carbo bioreactor, ensuring readiness for GMP manufacturing. This milestone reflects the ongoing investment KCL is making in their infrastructure, processes, and people, and underlines the focus on providing reliable and flexible GMP viral vector supply for early phase gene therapy programmes.

For further information on KCL’s capabilities and services, please contact henry.pegram@kcl.ac.uk.

Any questions on scale-X?